December 2, 2018 — 95% ORR (by IWG) in 20 evaluable patients 70% complete remission (CR) rate in 20 evaluable patients No dose-limiting toxicities to date BOSTON, MA. and STOCKHOLM, SWEDEN, December 2, 2018 – Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase
June 17, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm ORR (by IWG) of 100% in all evaluable
April 16, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago ORR (by IWG) of 100% in all
January 4, 2018 —BOSTON, MA., and STOCKHOLM, SWEDEN, January 4, 2018 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.
October 16, 2017 —BOSTON, MA. and STOCKHOLM, SWEDEN, October 16, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patients were enrolled in a Phase
August 2, 2017 —BOSTON, MA. and STOCKHOLM, SWEDEN, August 2, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patient was enrolled in a Phase Ib/II
May 24, 2017 —BOSTON, MA., and STOCKHOLM, SWEDEN, May 23, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patient was enrolled in the Phase Ib/II
March 22, 2017 —BOSTON, MA., and STOCKHOLM, SWEDEN, March 22, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced a collaboration with Memorial Sloan Kettering Cancer
January 7, 2017 — BOSTON, MA. and STOCKHOLM, SWEDEN, January 5, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.
October 22, 2016 —Dr. Mikael von Euler will present data from Aprea Therapeutics’ Phase Ib study in high-grade serous ovarian cancer at the 7th International Mutant p53 Workshop in Melbourne, Australia . This oral presentation is scheduled for 11:35 AM on Friday October 28, 2016 as part of Session
